Giuseppe Fornarini - Concepedia

Author

Giuseppe Fornarini

Also Known As

A Passarelli, Fornarini, G, Fornarini, Giuseppe, G. Fornarini, G. fornarini, GIUSEPPE FORNARINI, Giuseppe Fornarini, Luigi Formisano, P. Sozzi, V. Pensotti

297

Publications

4.5K

Citations

H-Index

Concepts

All Affiliations

Ospedale Policlinico San Martino Istituti di Ricovero e Cura a Carattere Scientifico Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Istituto Oncologico Veneto University of Parma

About

Giuseppe Fornarini is an author at Ospedale Policlinico San Martino specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	32	1.2K
2	Health Sciences	6	6	219
3	Public Health	2	2	38
4	Epidemiology	1	1	22
5	Immunology	1	1	53

Giuseppe Fornarini

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, New England Journal of Medicine	2024	764
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab Ugo De Giorgi, Giuseppe Procopio, Diana Giannarelli, Clinical Cancer Research	2019	233
Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa Paolo Pedrazzoli, A. Farris, Salvatore Del Prete, Journal of Clinical Oncology	2008	167
LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC) Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, Annals of Oncology UrologyGenitourinary CancerMedicineEnfortumab VedotinImmune Checkpoint Inhibitor	2023	131
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trial Roberto Labianca, Alberto F. Sobrero, L. Isa, Annals of Oncology Surgical OncologyGastrointestinal OncologyMedicineColorectal CancerSurgery	2010	108
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Therapeutic Advances in Medical Oncology	2021	86
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study Orazio Caffo, Ugo De Giorgi, Lucia Fratino, European Urology Italian Multicentre StudyUrologyGenitourinary CancerMedicineOther Second-line Treatment	2014	83
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme Ugo De Giorgi, Giacomo Cartenì, Diana Giannarelli, British Journal of Urology	2018	82
Phase II Study of Oxaliplatin and Gemcitabine Salvage Chemotherapy in Patients with Cisplatin-Refractory Nonseminomatous Germ Cell Tumor Ugo De Giorgi, Giovanni Rosti, Michele Aieta, European Urology UrologySurgical OncologyMedicineMetronomic TherapyPathology	2006	78
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study) Matteo Bauckneht, Sara Elena Rebuzzi, Alessio Signori, European Journal of Nuclear Medicine and Molecular Imaging	2021	76

Page 1